ZymoGenetics Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases such as hepatitis C, metastatic melanoma, psoriasis, diabetes, atopic dermatitis and more.

The company has secured collaboration agreements with Bristol-Myers Squibb Company (NYSE: BMY), Bayer Schering Pharma AG and Merck Serono S.A.

The company recently announced it has commenced the second part of a phase 2 clinical trial in collaboration with Bristol-Myers for investigational drug PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection.

In a phase 1b clinical trial, PEG-Interferon was administered in combination with ribavirin to patients with relapsed HCV.

“We’ve moved forward into part B of our phase 2 study of PEG-Interferon lambda in hepatitis C,” Eleanor L. Ramos, M.D., senior vice president and chief medical officer of ZymoGenetics stated in the press release. “In part B, we expect to generate a substantial body of data to inform the design of phase 3 studies, which will assess the potential role of PEG-Interferon lambda in addressing the unmet medical need for a safer, more effective treatment for hepatitis C.”

For more information on the company, visit www.zymogenetics.com.